Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials-Reference-Cited by-同舟云学术

Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials

Published:2018-08-20 Issue:3 Volume:58 Page:375-387
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Suleiman Ahmed A.,Khatri Amit,Minocha Mukul,Othman Ahmed A.

Funder

AbbVie

Boehringer Ingelheim

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/article/10.1007/s40262-018-0704-z/fulltext.html

Reference47 articles.

1. Patel DD, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity. 2015;43(6):1040–51.

2. McGovern D, Powrie F. The IL23 axis plays a key role in the pathogenesis of IBD. Gut. 2007;56(10):1333–6.

3. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev. 2008;226:57–79.

4. Bowes J, Barton A. The genetics of psoriatic arthritis: lessons from genome-wide association studies. Discov Med. 2010;10(52):177–83.

5. Smith RL, Warren RB, Eyre S, Ho P, Ke X, Young HS, et al. Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort. J Investig Dermatol. 2008;128(5):1325–7.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Pharmaceuticals and Therapeutics for Tumor Necrosis Factor-Alpha-Resistant Crohn's Disease: A Narrative Review;Cureus;2024-07-25

2. Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis;Clinical Pharmacology & Therapeutics;2024-06-11

3. Risankizumab to treat moderately to severely active Crohn’s disease in adults: an evaluation of trials and data;Expert Review of Gastroenterology & Hepatology;2023-12-02

4. Population Pharmacokinetic and Exposure–Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn's Disease;Clinical Pharmacology & Therapeutics;2023-01-20

5. Risankizumab-rzaa: A New Therapeutic Option for the Treatment of Crohn’s Disease;Annals of Pharmacotherapy;2022-10-08